- Home
- CUE vs NCSM Comparison
CUE vs NCSM Comparison
Compare CUE & NCSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- NCSM
- Stock Information
- Founded
- CUE 2014
- NCSM 2006
- Country
- CUE United States
- NCSM United States
- Employees
- CUE N/A
- NCSM N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- NCSM Oilfield Services/Equipment
- Sector
- CUE Health Care
- NCSM Energy
- Exchange
- CUE Nasdaq
- NCSM Nasdaq
- Market Cap
- CUE 60.6M
- NCSM 61.1M
- IPO Year
- CUE 2018
- NCSM 2017
- Fundamental
- Price
- CUE $0.76
- NCSM $28.64
- Analyst Decision
- CUE Strong Buy
- NCSM
- Analyst Count
- CUE 3
- NCSM 0
- Target Price
- CUE $3.00
- NCSM N/A
- AVG Volume (30 Days)
- CUE 206.6K
- NCSM 13.6K
- Earning Date
- CUE 05-08-2025
- NCSM 04-30-2025
- Dividend Yield
- CUE N/A
- NCSM N/A
- EPS Growth
- CUE N/A
- NCSM N/A
- EPS
- CUE N/A
- NCSM 2.55
- Revenue
- CUE $9,287,000.00
- NCSM $162,557,000.00
- Revenue This Year
- CUE N/A
- NCSM $7.03
- Revenue Next Year
- CUE $4.77
- NCSM $5.82
- P/E Ratio
- CUE N/A
- NCSM $11.23
- Revenue Growth
- CUE 69.16
- NCSM 14.10
- 52 Week Low
- CUE $0.45
- NCSM $15.90
- 52 Week High
- CUE $2.26
- NCSM $38.95
- Technical
- Relative Strength Index (RSI)
- CUE 39.49
- NCSM 46.67
- Support Level
- CUE $0.72
- NCSM $25.09
- Resistance Level
- CUE $0.89
- NCSM $28.95
- Average True Range (ATR)
- CUE 0.10
- NCSM 2.72
- MACD
- CUE 0.02
- NCSM -0.66
- Stochastic Oscillator
- CUE 48.59
- NCSM 25.62
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.
About NCSM NCS Multistage Holdings Inc.
NCS Multistage Holdings Inc provides products and support services that facilitate the optimization of oil and natural gas well completions and field development strategies. NCS provides its products and services to exploration and production companies for use in onshore wells, predominantly wells that have been drilled with horizontal laterals in unconventional oil and natural gas formations. The company's primary offering is its fracturing systems products and services, which enable efficient pinpoint stimulation: the process of individually stimulating each entry point into a formation targeted by an oil or natural gas well. Geographically, majority of revenue is generated from United States.